http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Eun-Do Kim,Jin-Kwon Lee,Jin-Kyu Cho,Jae-Myung Kim,Ji-Ho Park,Ju-Yeon Kim,Sang-Ho Jeong,Young-Tae Ju,Chi-Young Jeong,Eun-Jung Jung,Young-Joon Lee1,Soon-Chan Hong,곽승진 대한종양외과학회 2019 Korean Journal of Clinical Oncology Vol.15 No.2
Purpose: Whether subtotal or total colectomy with primary anastomosis (PA) is safer than Hartmann procedure (HP) for left-sided colon cancer obstruction or perforation remains controversial. The purpose of this study was to compare postoperative morbidity, mortality, and defecation frequency between PA and HP for left-sided colon cancer obstruction or perforation. Methods: This retrospective study enrolled 54 patients from January 2014 to February 2018 who underwent emergency surgery due to left-sided colon cancer obstruction or perforation. Results: PA was carried out in 20 patients while HP was performed for 34 patients. Thirty-day mortality did not show significant difference between the two groups (15.0% vs. 14.7%, P=1.000). No anastomotic leakage occurred in PA group while three (8.8%) cases of stump leakage occurred in HP group. Stoma repair was performed for 13 cases (44.8%) and stoma reformation was performed for one case in HP group (7.7%). Stoma related complications occurred in five cases (17.24%). For patients after stoma repair, defecation frequency at 3 months after operation was 2.91±2.88 times per day in PA group and 2.86±2.63 times per day in HP group. At 1 year after operation, defecation frequency was changed to 1.40±1.12 times per day in PA group and 1.17±0.39 times per day in HP group. Conclusion: Primary ileosigmoid or ileorectal anastomosis for left-sided colon cancer obstruction or perforation is safe, and shows similar outcome of defecation frequency compared to H
Clinical and Genetic Characteristics of Retinal Capillary Hemangioblastoma in Korean Patients
Sang Ha Lee(Sang Ha Lee),Kyu Hyung Park(Kyu Hyung Park),Se Joon Woo(Se Joon Woo),Sang Jun Park(Sang Jun Park),Kwangsic Joo(Kwangsic Joo) 대한안과학회 2022 Korean Journal of Ophthalmology Vol.36 No.6
Purpose: We investigated the clinical features of Korean patients with retinal capillary hemangioblastoma (RCH) and genetic variants of the von Hippel-Lindau (VHL) gene. Methods: A retrospective analysis was performed on patients with RCH from 2003 to 2021 at Seoul National University Bundang Hospital. Sporadic and hereditary RCH associated with VHL disease were classified based on the specific tumors and family history. Clinical features, including the location and number of RCH and bilateral involvement, were investigated. Multiplex ligation-dependent probe amplification and direct sequencing targeting the VHL gene were performed for six RCH cases associated with VHL disease. Results: A total of 18 patients (23 eyes) were enrolled in this study. The mean age at diagnosis was 37 ± 15 years. Twelve patients had hereditary RCH associated with VHL disease, and six patients had sporadic RCH. All five patients with bilateral RCH were clinically diagnosed with VHL disease, and 13 patients had unilateral RCH. Juxtapapillary RCH was only observed in patients with VHL. The most common complication of RCH was the epiretinal membrane, followed by the subretinal fluid. Pathogenic variants were identified in four patients. All three patients with type 1 VHL had the well-known missense mutation p.Glu70Lys, and one patient with type 2 VHL had the nonsense mutation p.Trp88Ter. Conclusions: In Korean patients with RCH, bilateral involvement and juxtapapillary RCH are highly likely to be associated with VHL disease. Because RCH may be the first clinical manifestation in patients with VHL, active genetic testing of the VHL gene and systemic evaluation are required.
한국형발사체 3단 과산화수소 추력기시스템 제어장치 아날로그 데이터 취득 스케줄링 변경을 통한 노이즈 측정오류 개선
이상현(Sang-Hyun Lee),송우근(Woo-Keun Song),오현명(Hyun-Myung Oh),이정운(Jung-Un Lee),이종철(Jong-Cheol Lee),박상준(Sang-Joon Park),이상빈(Sang-Bin Lee),이희중(Hee-Joong Lee),오상관(Sang-Gwan Oh),민병주(Byeong-Joo Min) 한국항공우주학회 2020 한국항공우주학회 학술발표회 논문집 Vol.2020 No.11
Inactivation of Brain Succinic Semialdehyde Reductase by o - Phthaldehyde
Lee, Su Jin,Choi, Soo Young,Cho, Sung Woo,Choe, Joon Ho,Jang, Sang Ho,Song, Min Sun,Lee, Byung Ryong,Park, Jin Seu 생화학분자생물학회 1976 BMB Reports Vol.28 No.2
Succinic semialdehyde reductase was inactivated by o-phthalaldehyde. The inactivation followed pseudo-first order kinetics, and the second-order rate constant for the inactivation process was 28 M^(-1)s^(-1) at pH 7.4 and 2590. The absorption spectrum (λ_(max) 337 nm) and fluorescence excitation (λ_(max) 340 nm) and fluorescence emission spectra (λ_(max) 409 nm) were consistent with the formation of an isoindole derivative in the catalytic site between a cysteine and a lysine residue approximately about 3 Å apart. The substrate, succinic semialdehyde, did not protect enzymatic activity against inactivation, whereas the coenzyme NADPH protected against o-phthaladehyde induced inactivation of the enzyme. About 1 isoindole group per ㏖ of the enzyme was formed following complete loss of enzymatic activity. These results suggest that the amino acid residues of the enzyme participating in a reaction with o-phthalaldehyde are cysteinyl and lysyl residues at or near the NADPH binding site.
Lee, Sang Sin,Kim, Soo Yeon,Im, Myung,Lee, Young,Seo, Young Joon,Lee, Jeung Hoon Korean Dermatological Association; The Korean Soci 2011 Annals of Dermatology Vol.23 No.suppl2
<P>Pseudocyst of the scalp is described in the Japanese literature as a skin-colored cystic tumor localized on the forehead, whereas alopecic and aseptic nodules of the scalp are described in the French literature as asymptomatic nodules on the scalp that lack a pseudocyst-like architecture. The etiology of these diseases is unknown, but the lesions are likely due to follicular occlusion. Here, we report a case of pseudocyst of the scalp in a 72-year-old woman. The patient had a dome-shaped painless tumor on her scalp. Histologic examination showed a pseudocyst-like architecture with no true cystic wall. Here, we report a case of pseudocyst of the scalp and summarize the characteristic features of both pseudocyst of the scalp and alopecic and aseptic nodules of the scalp.</P>
Lee, Hyeri,Riu, Myoungjoo,Kim, Eunhye,Moon, Joon-Kwan,Choi, Hoon,Do, Jung-A,Oh, Jae-Ho,Kwon, Ki-Sung,Lee, Young Deuk,Kim, Jeong-Han 한국응용생명화학회 2013 Applied Biological Chemistry (Appl Biol Chem) Vol.56 No.2
A single residue analytical method was developed for herbicide chlorpropham in various crops. Brown rice, apple, mandarin, Kimchi cabbage, green pepper, potato, and soybean were selected as representative crops, and clean-up system, partition solvent, and extraction solvent were optimized. For high performance liquid chromatography (HPLC), $C_{18}$ column was used with elution solvents of water and acetonitrile. Limit of quantitation (LOQ) of chlorpropham was 2 ng (S/N >20), and excellent linearity ($R^2$=1.000) was achieved. Method limit of quantitation (MLOQ) was 0.02 mg/kg. For recovery tests, crop samples were macerated and fortified with chlorpropham standard solution at three fortification levels (MLOQ, 10 MLOQ, and 100 MLOQ). And then those were extracted with acetonitrile, concentrated and partitioned with n-hexane. The n-hexane layer was then concentrated, cleaned-up through Florisil$^{(R)}$ column with ethyl acetate:n-hexane (5:95, v/v) prior to concentration and analysis with HPLC. Good recoveries from 76.8 to 107.9% with coefficients of variation of less than 10% were obtained, regardless of sample type, which satisfies the criteria of Korea Food and Drug Administration. Those results were confirmed with liquid chromatography-mass spectrometry (LC-MS). The method established in this study could be applied to most of crops as an official and general method for the analysis of chlorpropham residue.
Lee, Young-Suk,Kim, Na-Ri,Kim, Hyun-Ju,Joo, Hyun,Kim, Young-Nam,Jeong, Dae-Hoon,Cuong, Dang Van,Kim, Eui-Yong,Hur, Dae-Young,Park, Young-Shik,Hong, Yong-Geun,Lee, Sang-Kyung,Chung, Joon-Yong,Seog, Dae The Korean Society of Pharmacology 2004 The Korean Journal of Physiology & Pharmacology Vol.8 No.4
The purpose of the present study was to evaluate the expression of cardiac marker protein in rabbit cardiac tissue that was exposed to ischemic preconditioning (IPC), or ischemiareperfusion injury (IR) using two-dimensional gel electrophoresis (2DE) and matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS). We compared 2DE gels of control (uninjured) cardiac tissue with those of IPC and IR cardiac tissue. Expression of one protein was detected in IR heart tissue, however the protein was not detected in the samples of control and IPC tissue. To further characterize the detected protein molecule, the protein in the 2D gel was isolated and subjected to trypsin digestion, followed by MALDI-MS. The protein was identified as myoglobin, which was confirmed also by Western blot analysis. These results are consistent with previous studies of cardiac markers in ischemic hearts, indicating myoglobin as a suitable marker of myocardial injury. In addition, the present use of multiple techniques indicates that proteomic analysis is an appropriate means to identify cardiac markers in studies of IPC and IR.
Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort
Lee, Woo-Jin,Lee, Soon-Tae,Byun, Jung-Ick,Sunwoo, Jun-Sang,Kim, Tae-Joon,Lim, Jung-Ah,Moon, Jangsup,Lee, Han Sang,Shin, Yong-Won,Lee, Keon-Joo,Kim, Soyun,Jung, Keun-Hwa,Jung, Ki-Young,Chu, Kon,Lee, Sa Ovid Technologies (Wolters Kluwer) - American Acad 2016 Neurology Vol.86 No.18
<P>Objective: To determine efficacy and safety of rituximab treatment as a second-line immunotherapy treatment for autoimmune limbic encephalitis (ALE) and to determine factors associated with functional improvement and favorable outcome following rituximab treatment. Methods: We recruited 80 patients with ALE who were treated with rituximab as a second-line immunotherapy from the Korea Autoimmune Synaptic and Paraneoplastic Encephalitis Registry and reviewed 81 patients without rituximab as a control. We grouped patients according to the detection or type of antibodies; in addition, we evaluated clinical, laboratory, first-line immunotherapy, and rituximab treatment profiles and defined main outcomes as improvements on the modified Rankin Scale (mRS) score and a favorable mRS score (0-2) at the last follow-up. Results: Functional improvement occurred more frequently in the rituximab group compared to the control group. In the rituximab group, 30 (37.5%) patients had synaptic autoantibodies, 15 (18.8%) in the paraneoplastic autoantibodies, and 35 (43.8%) were antibody-negative. The effect of rituximab was the same regardless of autoantibody status. Additional monthly rituximab therapy and partial response to first-line immunotherapies were associated with mRS score improvements, as well as favorable mRS scores. mRS scores of 4-6 as the worst neurologic status predicted an unfavorable mRS score. There were no reported serious infusion-related or infectious adverse effects of rituximab. Conclusions: Rituximab is effective and safe as a second-line immunotherapy for ALE, regardless of autoantibody status. Additional monthly rituximab therapy might potentiate the efficacy of rituximab. Classification of evidence: This study provides Class IV evidence that rituximab improves mRS scores for patients with autoimmune limbic encephalitis who fail first-line therapy.</P>
( Joon Chang Song ),( Bo Young Min ),( Jin Wook Kim ),( Jong Yeop Kim ),( Yeo Myeong Kim ),( Cheol Min Shin ),( Sang Hyub Lee ),( Jin Hyeok Hwang ),( Sook Hyang Jeong ),( Na Young Kim ),( Dong Ho Lee 대한간학회 2011 Clinical and Molecular Hepatology(대한간학회지) Vol.17 No.4
Background/Aims: Decay of hepatitis B surface antigen (HBsAg) titers has previously been shown to be predictive of a virologic response (VR), especially during peginterferon-alpha therapy. However, the role of HBsAg levels in predicting a VR to nucleos(t)ide analog therapy has not yet been established. In this study we sought to determine whether the VR can be predicted from HBsAg titers in nucleos(t)ide-naive chronic hepatitis B (CHB) patients treated with entecavir. Methods: CHB patients who started entecavir as an initial antiviral therapy were enrolled in this study. Serum hepatitis B virus (HBV) DNA, HBsAg, and alanine aminotransferase levels were measured every 3 months during treatment. A VR was defined as undetectable serum HBV DNA titer by real-time PCR assay (<60 IU/mL). Results: Fifty-two patients were enrolled, and the median duration of treatment was 26 months (range 7-35 months). Forty-five patients achieved a VR; the cumulative VR rates at 3, 6, 12, and 24 months were 40%, 71.2%, 81.5%, and 88%, respectively. Baseline HBV DNA levels were significantly lower in patients with VR, whereas the HBsAg levels did not differ significantly between patients with or without VR. In a univariate analysis the cumulative VR rate was significantly higher in HBeAg negative patients and patients with an HBsAg/HBV DNA ratio above 0.56. However, in a multivariate analysis only an HBsAg/HBV DNA ratio above 0.56 was an independent predictor of VR (P=0.003). The area under the receiver operating characteristic curve was larger for the HBsAg/HBV DNA ratio than for either HBV DNA or HBsAg. Conclusions: Pretreatment HBsAg/HBV DNA ratio can predict a long-term VR to entecavir therapy in nucleos(t)ide-naive CHB patients. (Korean J Hepatol 2011;17: 268-273)
Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study
Lee, Woo-Jin,Lee, Soon-Tae,Moon, Jangsup,Sunwoo, Jun-Sang,Byun, Jung-Ick,Lim, Jung-Ah,Kim, Tae-Joon,Shin, Yong-Won,Lee, Keon-Joo,Jun, Jin-Sun,Lee, Han Sang,Kim, Soyun,Park, Kyung-Il,Jung, Keun-Hwa,Jun Springer-Verlag 2016 Neurotherapeutics Vol.13 No.4
<P>A considerable portion of autoimmune encephalitis (AE) does not respond to conventional immunotherapies and subsequently has poor outcomes. We aimed to determine the efficacy of tocilizumab, an anti-interleukin-6 antibody, in rituximab-refractory AE compared with other treatment options. From an institutional cohort of AE, 91 patients with inadequate clinical response to first-line immunotherapy and following rituximab were retrospectively reviewed. Patients were grouped according to their further immunotherapy strategies. Thirty (33.0 %) patients were included in the tocilizumab group, 31 (34.0 %) in the additional rituximab group, and 30 (33.0 %) in the observation group. Outcomes were defined as the favorable modified Rankin Scale scores (aecurrency sign2) at 1 and 2 months from the initiation of each treatment strategy and at the last follow-up. Favorable clinical response (improvement of the modified Rankin Scale scores by aeyen 2 points or achievement of the mRS scores aecurrency sign 2) at the last follow-up was also analyzed. The tocilizumab group showed more frequent favorable mRS scores at 2 months from treatment initiation and at the last follow-up compared with those at the relevant time points of the remaining groups. The majority (89.5 %) of the patients with clinical improvement at 1 month from tocilizumab treatment maintained a long-term favorable clinical response. No serious adverse effects of rituximab or tocilizumab were reported. Therefore, we suggest that tocilizumab might be a good treatment strategy for treating AE refractory to conventional immunotherapies and rituximab. The tocilizumab-mediated clinical improvement manifests as early at 1 month after treatment initiation.</P>